Article Text

PDF
SAT0037 Serum 14-3-3Eta Predicts the Risk of RA Development and Its Higher Titres Are Associated with Higher Risk
  1. D. van Schaardenburg1,
  2. W.P. Maksymowych2,
  3. M. Boers3,
  4. M.H. van Beers-Tas4,
  5. A. Marotta5
  1. 1Reade, Amsterdam, Netherlands
  2. 2University of Alberta, Edmonton, Canada
  3. 3VU University Medical Center
  4. 4Reade, Amsterdam, Netherlands
  5. 5Augurex, Vancouver, Canada

Abstract

Background 14-3-3eta (η) is a mechanistic biomarker that is useful in RA diagnosis. We have previously reported that its plasma expression precedes and independently predicts RA development in arthralgia subjects. 14-3-3η titres further improve the predictive value of variables such as ACPA, number of painful joints and alcohol non-use, which are independently associated with RA development.

Objectives To determine whether higher 14-3-3η serum cut-off informs a higher likelihood of RA development in arthralgia patients.

Methods 14-3-3η plasma levels were measured in 148 consecutive arthralgia patients of whom 44 (30%) developed RA [median time to RA, 14.5 months, range (1-68)] and 104 did not. Entry into the cohort was based on the absence of clinical arthritis at baseline but a positive ACPA and/or IgM-RF status and a history of arthralgia. 14-3-3η positivity was defined by the diagnostic cut-off of ≥0.19 ng/ml and a second cut-off of ≥0.80 ng/ml was set at the 75th percentile serum level of the group that did not develop RA. Fisher exact test and stepwise multivariate analyses were performed to determine 14-3-3η's association with other clinical/serological markers for RA development risk. Variables included in the model were ACPA positivity, alcohol non-use, VAS pain, morning stiffness and number of total painful joints.

Results 14-3-3η median plasma levels were significantly higher in the group that developed RA [0.9 (0.2-6.9) vs 0.3 (0.2-0.8) ng/ml, p<0.004]. ACPA levels were also differentially expressed (407 vs 54 IU/ml, p<0.001). Age, gender and RF titres did not differ between the groups. The Fisher exact test revealed that 14-3-3η levels at ≥0.19 ng/ml were associated with RA development with a likelihood ratio (LR) of 5.7 (p=0.02), a relative risk (RR) of 2.2 (95%CI: 1.0-4.5) and more significantly so at ≥0.80 ng/ml with an LR of 9.3 (p=0.002) and a RR of 2.2 (95%CI, 1.3-3.5). Alcohol non-use 1.7 (95%CI: 1.1-2.8), p=0.02 and ACPA positivity 7.9 (95%CI: 2.6-24.1), p<0.0001 but not RF, were also associated with RA development. In a multivariate analysis including these variables, 14-3-3η expression independently predicted RA development with a LR of 4.0 (p=0.05) at the ≥0.19ng/ml cut-off and more strongly so at the higher ≥0.80 ng/ml cut-off with a LR=5.9 (p=0.02).

Conclusions Plasma 14-3-3η titres are independently associated with RA development and levels ≥0.80 ng/ml are associated with a higher likelihood of developing RA. These findings are consistent with the mechanistic understanding of 14-3-3η's deleterious role in the pathophysiology of RA.

Disclosure of Interest D. van Schaardenburg: None declared, W. Maksymowych Consultant for: Augurex Life Sciences Corp, M. Boers: None declared, M. van Beers-Tas: None declared, A. Marotta Employee of: Augurex Life Sciences Corp

DOI 10.1136/annrheumdis-2014-eular.3326

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.